Stay updated on Dapagliflozin Impact on T2DM Risk Factors Clinical Trial
Sign up to get notified when there's something new on the Dapagliflozin Impact on T2DM Risk Factors Clinical Trial page.

Latest updates to the Dapagliflozin Impact on T2DM Risk Factors Clinical Trial page
- Check7 days agoChange DetectedThere are no additions or deletions to report. The page content appears unchanged with respect to the study details and related sections.SummaryDifference0.1%

- Check14 days agoChange DetectedThe page revision line was updated from v3.6.3 to v3.6.4. This indicates a minor update to the page's version metadata rather than to the study details.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedThe page now shows Revision: v3.6.3, replacing the previous v3.6.2, indicating a minor version update to the study record page. This metadata change does not modify the study details.SummaryDifference0.1%

- Check42 days agoChange DetectedThe page revision indicator was updated from v3.6.0 to v3.6.2, reflecting a minor update to the page version without changing its content.SummaryDifference0.1%

- Check50 days agoChange DetectedThe page now includes related topics such as Type 2 diabetes and MedlinePlus Genetics, adding links to genetics-related health information.SummaryDifference0.2%

- Check57 days agoChange DetectedThe Study Details page now includes Manfredi Rizzo as part of the study record information and adds new navigation items such as How to Read a Study Record, Common Questions, How to Join a Study, and an updated Intervention/Treatment label. Legacy text such as Last known status was, Verified, Manfredi Rizzo, University of Palermo, Intervention / Treatment, and the prior Revision: v3.5.5 has been removed, with Revision: v3.6.0 introduced.SummaryDifference2%

Stay in the know with updates to Dapagliflozin Impact on T2DM Risk Factors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dapagliflozin Impact on T2DM Risk Factors Clinical Trial page.